Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-09-09 08:00 |
Biophytis renforce son équipe de direction avec la nomination d’un nouveau Dire…
|
French | 182.7 KB | ||
| 2021-08-16 08:00 |
Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC…
|
English | 556.9 KB | ||
| 2021-08-16 08:00 |
Biophytis reçoit une recommandation favorable du DMC pour poursuivre le recrute…
|
French | 168.4 KB | ||
| 2021-08-13 23:00 |
Biophytis annonce l’émission de 4.950.000 actions nouvelles dans le cadre d’une…
|
French | 142.1 KB | ||
| 2021-08-13 23:00 |
Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Res…
|
English | 539.5 KB | ||
| 2021-08-02 08:00 |
BIOPHYTIS ANNOUNCES TOP LINE RESULTS OF SARA-INT PHASE 2 STUDY WITH SARCONEOS (…
|
English | 474.9 KB | ||
| 2021-08-02 08:00 |
BIOPHYTIS ANNONCE LES PREMIERS RÉSULTATS DE L'ÉTUDE DE PHASE 2 SARA-INT AVEC SA…
|
French | 102.7 KB | ||
| 2021-07-19 23:00 |
Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Neg…
|
English | 213.1 KB | ||
| 2021-07-19 23:00 |
Jugement du Juge de l'exécution du Tribunal judiciaire de Paris du 16 juillet 2…
|
French | 215.1 KB | ||
| 2021-07-12 08:00 |
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 …
|
English | 175.7 KB | ||
| 2021-07-12 08:00 |
Biophytis présente des données précliniques positives sur Sarconeos (BIO101) po…
|
French | 212.7 KB | ||
| 2021-07-08 08:00 |
Biophytis Reinforces Leadership Teams with Three Senior Appointments
|
English | 214.5 KB | ||
| 2021-07-08 08:00 |
Biophytis Renforce ses Equipes de Direction avec Trois Nouvelles Nominations
|
French | 228.2 KB | ||
| 2021-06-30 23:00 |
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a G…
|
English | 139.1 KB | ||
| 2021-06-30 23:00 |
Biophytis Sécurise la Fabrication de Sarconeos (BIO101) dans le Traitement de l…
|
French | 164.2 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
